BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
6 Exercises to Anticipate in 2024- 6 Solid Moving Administrations for a Calm Movement
- American tourists left stranded in the Caribbean following flight cancellations after airspace closed for Maduro operation
- Germany and trade unions kick off tough public-sector wage talks
- Trump administration launches new immigration crackdowns in New Orleans and Minneapolis. Here are all the cities it has targeted so far.
- Tourist trade in Greece and Cyprus suffering from Iran war effects
- Courageous Climbing: Trails and Stuff for Outside Lovers
- 4K televisions for Extreme Film Watching Experience
- Architect Frank Gehry has died: See his most iconic buildings
